Day: March 28, 2024

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

Company to Host Conference Call Today, March 28, at 4:30pm ET BOCA RATON, Fla., March 28, 2024 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the year ended December 31, 2023 and provides a business update. Q4 2023 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™):The AD02 randomized, blinded program for patients with Early Alzheimer’s Disease remains on schedule to reach its final enrollment target by mid-2024, with top-line data expected to be presented approximately six months after the last patient is enrolled. The trial is currently active in North America, UK, EU, and the Pacific Rim. INmune Bio...

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024 SEATTLE and VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end 2023 financial results and provided an update on the cytisinicline development program. Recent HighlightsAnnounced Company reached agreement with the U.S. Food and Drug Administration (FDA) on long-term cytisinicline exposure requirements to support a New Drug Application (NDA) submission Completed an equity financing of up to $124.2 million that included initial upfront gross proceeds of $60.0 million, prior to deducting placement agent...

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results from interim analysesThe clinical study reports for FURI, CARES and NATURE in refractory invasive fungal infections are on target for delivery to GSK in the first half of 2024 which would trigger a $10 million development milestone payment to SCYNEXISSCYNEXIS ended 2023 with cash, cash equivalents and investments of $98.0 million and projects a cash runway of more than two yearsJERSEY CITY, N.J., March 28, 2024 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent...

CNL STRATEGIC CAPITAL ANNOUNCES OPERATING RESULTS FOR YEAR-END 2023

Written by Customer Service on March 28, 2024. Posted in Earnings Releases And Operating Results.

Orlando, Fla., March 28, 2024 (GLOBE NEWSWIRE) — CNL Strategic Capital, LLC (“CNL Strategic Capital,” the “Company” or “we”) seeks to provide current income and long-term appreciation to investors by acquiring controlling equity stakes in combination with loan positions in privately owned middle-market businesses. The Company announced its operating results for the year ended Dec. 31, 2023. Highlights:As of Dec. 31, 2023, CNL Strategic Capital’s portfolio consisted of equity and debt investments in 13 portfolio companies and approximately $1.0 billion in total assets, compared with approximately $732.5 million as of Dec. 31, 2022. For the year ended Dec. 31, 2023, the Company recognized a net change in unrealized appreciation on investments of approximately $41.7 million and had total investment income of approximately $59.5...

Omega Flex, Inc. Announces Regular Quarterly Dividend for the First Quarter 2024

Written by Customer Service on March 28, 2024. Posted in Dividend Reports And Estimates.

EXTON, Pa., March 28, 2024 (GLOBE NEWSWIRE) — Omega Flex, Inc. (the “Company”) (NASDAQ: OFLX) today announced that the Board of Directors declared a regular quarterly dividend of $0.33 per share payable on April 24, 2024, to shareholders of record on April 10, 2024. In determining the amount of future regular quarterly dividends, the Board will review the cash needs of the Company, and based on results of operations, financial condition, capital expenditure plans, and consideration of possible acquisitions, as well as such other factors as the Board of Directors may consider relevant, determine on a quarterly basis the amount of a regular quarterly dividend. INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS – This press release contains forward-looking statements, which are subject to inherent uncertainties which are difficult...

Esports Entertainment Group Announces Upgrade to the OTCQB

Written by Customer Service on March 28, 2024. Posted in Public Companies.

St. Julian’s, Malta, March 28, 2024 (GLOBE NEWSWIRE) — Esports Entertainment Group, Inc. (OTCQB: GMBL) (OTCQB: GMBLP) (“Esports Entertainment Group”, “EEG”, or the “Company”), a leading, global iGaming company and business-to-business (B2B) esports content and solutions provider, today announced its common stock, trading under the symbol GMBL, par value $0.001, and 10% Series A Cumulative Redeemable Convertible Preferred Stock, trading under the symbol GMBLP, have been approved for upgraded quotation on the OTCQB Venture Market, effective as of March 28, 2024. OTCQB is a venture market operated by the OTC Markets Group Inc. To be eligible for quotation on the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process. OTCQB is recognized by the U.S. Securities and...

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

Written by Customer Service on March 28, 2024. Posted in Public Companies.

– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned cancer institutions – BOSTON, March 28, 2024 (GLOBE NEWSWIRE) — In a release issued under the same headline on March 25 by AVEO Pharmaceuticals, the text in the second paragraph has been corrected to better reflect Dr. Braendle’s clinical research experience. The corrected release follows: AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical...

Orange: Publication of the 2023 Universal Registration Document

Written by Customer Service on March 28, 2024. Posted in Public Companies.

Press releaseParis, 28 March 2024Publication of the 2023 Universal Registration DocumentOn 28 March 2024, Orange filed its 2023 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in France in ESEF format. The document includes the following information:the 2023 Annual Financial Report; the Report of the Board of Directors on Corporate Governance; the Consolidated Non-Financial Statement, information on the next Combined Ordinary and Extraordinary Shareholders’ Meeting of 22 May 2024.The Registration Document is available to the public on Orange’s corporate website: https://www.orange.com/en/regulated-information. About Orange Orange is one of the world’s leading telecommunications operators with revenues of 44.1 billion euros in 2023 and 137,000 employees worldwide at 31 December 2023, including...

Genetron Health Announces Completion of Going Private Transaction

Written by Customer Service on March 28, 2024. Posted in Mergers And Acquisitions.

BEIJING, March 28, 2024 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the “Merger”) with Genetron New Co Limited (“Merger Sub”), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”), among the Company, New Genetron Holding Limited (“Parent”) and Merger Sub. As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and will cease to be a publicly traded company. Pursuant to the terms of the Merger Agreement, which was approved by the Company’s shareholders at an...

ABO-Group Environment Annual Results 2023

Written by Customer Service on March 28, 2024. Posted in Public Companies.

Ghent, 28 March 2024 – 18.30 CET – Press release / regulated information 2023 highlightsABO-GROUP saw her revenue grow by 20%, to €85.2 million, thanks to 5 acquisitions and 10% organic growth The EBITDA margin increased by 13% on a year-to-year basis, thanks to the smooth integration of the acquisitions A solid balance sheet with a debt ratio of 1.5x EBITDA, and a solvency ratio of 30%OutlookStrengthening of the existing areas of expertise, with a focus on the growth drivers ecology, PFAS and the mining industry Continued focus on M&A: Eau & Perspectives, ABO-GROUP’s first acquisition in 2024 The “€100 million revenue” mark within reach, quicker than plannedFrank De Palmenaer, CEO ABO-GROUP Environment: “This year, ABO-GROUP succeeded in realising the strongest performance in recent years, growing by 20%....

Day: March 28, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice